Company: CERO
Filing Date: 2025-05-07
Form Type: DEF 14A
Source: 0001213900-25-040263
Chunk: 88

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-05-07
Form: DEF 14A
Chunk 88
---
 Pierce Consulting Agreement has an initial term of twelve months, commencing October 1, 2024, as may be extended by mutual written agreement. Dr. Pierce will receive a monthly fee of $30,000 for her services during the term of the Pierce Consulting Agreement. In addition, Dr. Pierce received an award of 2,000 options to purchase shares of Common Stock, which will vest in equal monthly installments over twenty -fourmonths, subject to Dr. Pierce’s continued service; provided, that the vesting of 50% such options shall be accelerated upon the FDA’s acceptance of our IND. Either party may terminate the Pierce Consulting Agreement at any time with at least 30 days’ prior written notice. Outstanding Equity Awards as of December 31, 2024 The following table sets forth information regarding outstanding equity awards held by our named executive officers as of December 31, 2024:

| Name                           |     | Grant Date |     | Vesting      
 Commencement 
 Date         |     | Option Awards 
     Number of 
    Securities 
    Underlying 
   Unexercised 
   Options (#) 
   Exercisable |     |     Number of 
    Securities 
    Underlying 
   Unexercised 
   Options (#) 
 Unexercisable |     | Option   
 Exercise 
 Price    
 ($)      |       |     | Option     
 Expiration 
 Date       |
|:-------------------------------|:----|:-----------|:----|:-------------|:----|--------------:|:----|--------------:|:----|:---------|------:|:----|:-----------|
| Chris Ehrlich,                 
 Chief Executive Officer        |     | 10/01/2024 |     | 12/02/2024   |     |        25,550 |     |             — |     | $        | 10.00 |     | 09/30/2034 |
| Brian G. Atwood,               
 Former Chief Executive Officer |     | 10/01/2024 |     | 12/02/2024   |     |         5,080 |     |             — |     | $        | 10.00 |     | 09/30/2034 |
| Andrew “Al” Kucharchuk,        
 Chief Financial Officer        |     | 10/01/2024 |     | 10/01/2024   |     |         1,250 |